A worrying report was published by Reuters regarding the suspension of over three hundred generic drug approvals and applications due to ‘unreliable’ tests at Indian contract research firm Micro Therapeutic Research Labs.
A recent systematic review found no benefit for the use of cannabinoids in the management of acute pain. Conversely, a number of systematic reviews have suggested that cannabinoids are beneficial in the management of chronic pain.
The results of a phase 2 dose-finding study (ORION-1) were recently published in the NEJM by Kausik et al.
The NEJM (New England Journal of Medicine) are keeping up with the times, and producing short videos. The new research findings on the controversial cardiovascular safety of celecoxib are summarised in this video on their website. It’s less than three minutes long, so grab a cup of tea and check it out here.